Aplisol Market Report 2026

Aplisol Market Overview

• The Aplisol market growth in the historic period has been driven by global tuberculosis burden, public health screening initiatives • Market expansion is supported by renewed tb surveillance efforts, migration related screening needs • Growth Driver: Aplisol Market Benefits From Growing Tuberculosis (TB) Prevalence • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Aplisol Market?

Aplisol is a purified protein derivative (PPD) skin test used to detect tuberculosis (TB) infection. It is injected intradermally to assess the body's immune response to Mycobacterium tuberculosis antigens. A positive reaction indicates possible exposure to TB, although further diagnostic testing is required to confirm active infection. The main indication types of aplisol are tuberculosis testing and BCG-vaccinated individuals. Tuberculosis (TB) testing refers to the diagnostic procedures used to detect infection with the Mycobacterium tuberculosis bacteria, which causes TB. The distribution channels are hospitals, clinics, and pharmacies, and end users include adults, geriatrics, and pediatrics.

What Is The Aplisol Market Growth Forecast?

The growth in the forecast period can be attributed to renewed tb surveillance efforts, migration related screening needs, public health funding growth, early infection detection focus, expanded preventive care programs. Major trends in the forecast period include continued use of tuberculosis skin testing, public health screening programs, hospital and clinic based tb surveillance, focus on latent tb detection, occupational health testing demand.

What Are The Drivers Of The Aplisol Market?

The rise in the prevalence of tuberculosis (TB) is expected to propel the growth of the aplisol market going forward. Tuberculosis (TB) is a contagious bacterial infection primarily affecting the lungs, caused by Mycobacterium tuberculosis, and can spread to other parts of the body if left untreated. The prevalence of Tuberculosis is rising due to factors such as the spread of drug-resistant strains, co-infection with HIV, socioeconomic conditions, increased global mobility, underreporting in healthcare systems, and delayed treatment due to stigma. Aplisol is essential for tuberculosis (TB) diagnosis as it is used in the Mantoux tuberculin skin test (TST), a primary method for detecting both latent and active TB infections. For instance, in February 2024, according to the UK Health Security Agency, a UK-based government agency, the total TB cases in the United Kingdom in 2022 accounted for 4380 which increased by 10.7% to reach 4850 in 2023. Therefore, the rise in the prevalence of tuberculosis (TB) drives the aplisol industry. The rise in healthcare expenditure is expected to propel the growth of the aplisol market going forward. Healthcare expenditure refers to the total amount of financial resources spent on medical services, healthcare infrastructure, pharmaceuticals, and healthcare-related activities. Healthcare expenditure is rising due to factors such as an aging population, increasing prevalence of chronic and lifestyle-related diseases, advances in medical technology, and greater access to healthcare services. Aplisol, a tuberculin skin test used for diagnosing tuberculosis, contributes to healthcare expenditure by incurring costs for testing, diagnosis, and follow-up procedures in at-risk populations. For instance, in May 2024, according to a report published by Office For National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the increase in healthcare expenditure drives the aplisol industry.

Key Players In The Global Aplisol Market

Major companies operating in the aplisol market are JHP Pharmaceuticals LLC

What Are Latest Mergers And Acquisitions In The Aplisol Market?

In April 2024, Endo Inc., a US-based pharmaceutical company acquired Endo International plc for an undisclosed amount. Following the acquisition, Endo Inc. aims to diversify its product portfolio and add innovative drug candidates to its pipeline. Endo International plc is a US-based pharmaceutical company focused on specialty branded pharmaceuticals.

What Defines the Aplisol Market?

The aplisol market consists of sales of TST kits, Aplisol solutions, diagnostic reagents, and TST injection devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Aplisol Market Report 2026?

The aplisol market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the aplisol industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.